20-year business development veteran will drive Aventiv’s continued growth in the early pharmaceutical sciences market.
COLUMBUS, OH, February 15, 2020 /24-7PressRelease/ — Aventiv Research announced today that Robert Wessel has joined the organization as director of business development for its Phase 1 clinical pharmacology facility. “Wessel will lead business development in Columbus to support Aventiv’s continued growth in the early pharmaceutical sciences market and our commitment to delivering industry-best data to our sponsors,” stated Dr. Samir Arora, President and Medical Director of Aventiv Research.
Aventiv is already a successful network of independent, trend focused, specialty based clinical research sites. “My goal is to build upon our existing capabilities to leverage the company’s early clinical pharmacology offerings and for Aventiv to be known as an industry leader in Phase 1 clinical trial research,” added Wessel.
Before joining Aventiv, Wessel spent more than 20 years as a business development executive where he monetized industry relationships for leading early clinical development CROs. Additionally, he received a degree in biology from Bellarmine College and attended the St. Louis University School of Medicine.
Aventiv’s inpatient clinical pharmacology unit is in Columbus at 99 N. Brice Road, Suite 260, neighboring Mount Carmel East. The facility offers Phase 1 pharmaceutical, device, and diagnostic clinical trials in an 8,000 square foot facility featuring 30 beds, private exam rooms, and multiple recreational and relaxation areas for patients.
For more information about Robert Wessel and clinical trials at Aventiv Research, visit https://www.aventivresearch.com/.
About Aventiv Research
Aventiv Research exists to make novel medicines accessible to its patients and deliver industry-best pharmaceutical data to its sponsors. Its mission is to enrich the lives of both its team members and patients by putting medical research to work. Currently operating in three states with five independent research sites, Aventiv specializes in phase I-IV pharmaceutical, device, and diagnostic clinical trials in a variety of therapeutic areas. Built on the core values of dedication, integrity, resourcefulness, and professionalism, the company embraces a visionary, entrepreneurial spirit that compels its ambassadors to blaze new trails with proprietary systems and processes.
Founded in 2007 by Dr. Samir Arora, a proven leader with more than 15 years of clinical research experience, Aventiv Research has conducted over 450 clinical trials with more than 55 pharmaceutical sponsors and has helped 12 drugs to become approved by the FDA and available for use.
For the original version of this press release, please visit 24-7PressRelease.com here